Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish company’s CagriSema drug fell short of investors’ expectations.
Multiplication and division are too slow for Opus 4.6.
，更多细节参见51吃瓜
– character identity
address this issue.
Courtesy of Sharge